GRTS - Gritstone bio rallies after U.S. patent win for mRNA-based vaccine tech

• Clinical-stage biotech Gritstone bio ( NASDAQ: GRTS ) added ~13% in the morning hours Tuesday after the company announced that the U.S. regulators issued two new patents related to its self-amplifying mRNA (samRNA) vaccine platform technology.
• The U.S. Patent No. 11,504,421 issued by the Patent and Trademark Office (USPTO) covers Gritstone’s ( GRTS ) lead product candidate, GRANITE, which is in development as an individualized cancer vaccine for solid tumors.
• The U.S. Patent No. 11,510,973 protects the company’s claims for the antigen-encoding samRNA vectors and has broad applicability across Gritstone’s candidates in oncology and infectious disease,” Gritstone ( GRTS ) said.
• The company shares surged in October after Piper Sandler initiated its coverage with an Overweight recommendation.
• Gritstone’s ( GRTS ) rivals in the self-amplifying mRNA space include Arcturus Therapeutics ( ARCT ), which announced a licensing deal with a unit of CSL Limited ( OTCPK:CSLLY ) ( OTCPK:CMXHF ) in November to advance the technology against respiratory infections.

For further details see: